Clinical Trial Update: Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating arsenic trioxide (Trisenox), ascorbic acid, and bortezomib in relapsed/refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Ascorbic acid (Vitamin C)
• Bortezomib (bortezomib)
• Trisenox (arsenic trioxide)

Snippet

Sponsor: Duke University | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED